B. Metzler seel. Sohn & Co. Holding AG Takes $5.68 Million Position in HealthEquity, Inc. (NASDAQ:HQY)

B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of HealthEquity, Inc. (NASDAQ:HQY) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 69,339 shares of the company’s stock, valued at approximately $5,675,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC purchased a new position in HealthEquity during the 2nd quarter worth $35,000. Paladin Wealth LLC purchased a new position in shares of HealthEquity during the third quarter worth about $39,000. GAMMA Investing LLC increased its position in HealthEquity by 114.8% in the 2nd quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock valued at $51,000 after acquiring an additional 318 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in HealthEquity during the 2nd quarter valued at approximately $73,000. Finally, 1620 Investment Advisors Inc. purchased a new position in shares of HealthEquity in the 3rd quarter valued at approximately $112,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

Insider Buying and Selling

In other news, Director Frank Corvino sold 1,039 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total value of $99,847.90. Following the completion of the transaction, the director now owns 3,784 shares of the company’s stock, valued at $363,642.40. The trade was a 21.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Robert W. Selander sold 8,250 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the sale, the director now owns 54,719 shares in the company, valued at approximately $4,540,582.62. This trade represents a 13.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,536 shares of company stock worth $884,517 in the last ninety days. Insiders own 2.20% of the company’s stock.

HealthEquity Stock Up 0.3 %

HealthEquity stock opened at $102.67 on Wednesday. HealthEquity, Inc. has a fifty-two week low of $62.10 and a fifty-two week high of $103.12. The firm has a market capitalization of $8.97 billion, a price-to-earnings ratio of 85.56, a price-to-earnings-growth ratio of 1.55 and a beta of 0.52. The stock’s fifty day moving average is $86.10 and its two-hundred day moving average is $81.42. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10.

HealthEquity (NASDAQ:HQY) last posted its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The firm had revenue of $299.93 million during the quarter, compared to the consensus estimate of $284.48 million. Analysts predict that HealthEquity, Inc. will post 2.27 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Bank of America upped their price target on HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. The Goldman Sachs Group started coverage on shares of HealthEquity in a research note on Friday, November 15th. They issued a “neutral” rating and a $108.00 target price for the company. JMP Securities reiterated a “market outperform” rating and set a $105.00 price target on shares of HealthEquity in a research note on Wednesday, September 4th. Barrington Research restated an “outperform” rating and issued a $105.00 price objective on shares of HealthEquity in a research report on Friday, September 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $107.23.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.